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Abstract
Among epigenetic “writers”, “readers”, and “erasers”, the lysine methyltransferases G9a and GLP,
which catalyze mono- and dimethylation of histone H3 lysine 9 (H3K9me2) and non-histone
proteins, have been implicated in a variety of human diseases. A “toolkit” of well-characterized
chemical probes will allow biological and disease hypotheses concerning these proteins to be
tested in cell-based and animal models with high confidence. We previously discovered potent and
selective G9a/GLP inhibitors including the cellular chemical probe UNC0638, which displays an
excellent separation of functional potency and cell toxicity. However, this inhibitor is not suitable
for animal studies due to its poor pharmacokinetic (PK) properties. Here, we report the discovery
of the first G9a and GLP in vivo chemical probe UNC0642, which not only maintains high in vitro
and cellular potency, low cell toxicity, and excellent selectivity, but also displays improved in vivo
PK properties, making it suitable for animal studies.
Introduction
Protein lysine methylation catalyzed by protein lysine methyltransferases (PKMTs, also
known as histone methyltransferases (HMTs)) has been increasingly recognized as a major
signaling mechanism in eukaryotic cells.1–5 PKMTs target both histone and non-histone
substrates and display significant variation in their ability to catalyze mono-, di-, and/or
trimethylation.1, 3, 5–8 In the context of epigenetic gene regulation, the different states of
histone lysine methylation encode distinct signals and are recognized by a host of proteins
and protein complexes. More than 50 PKMTs have been identified to date and many of them
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have been implicated in various human diseases.1, 3, 9, 10 During the last several years, the
PKMT target class has received considerable attention from the drug discovery and
medicinal chemistry community. A number of selective small-molecule inhibitors, which
target the PKMT substrate binding groove,11–17 cofactor binding site,18–31 and a PRMT
(protein arginine methyltransferase) allosteric binding site,32, 33 have been reported.
However, well-characterized chemical probes34–36 of PKMTs that are suitable for cell-based
and animal studies are still rare. Such probes are invaluable tools for testing biological and
therapeutic hypotheses concerning the PKMTs and for their validation as drug targets.
G9a (also known as KMT1C (lysine methyltransferase 1C) or EHMT2 (euchromatic histone
methyltransferase 2)) and GLP (also known as KMT1D (lysine methyltransferase 1D) or
EHMT1 (euchromatic histone methyltransferase 1)) are two closely related proteins and
were initially identified as H3K9 (histone H3 lysine 9) methyltransferases.37, 38 They share
80% sequence identity in their respective SET (suppressor of variegation 3–9, enhancer of
zeste, and trithorax) domains.38 In addition to H3K9, G9a and GLP methylate many non-
histone proteins.39, 40 For example, G9a and GLP catalyze dimethylation of the tumor
suppressor p53, resulting in inactivation of the transcriptional activity of p53.6 G9a is
overexpressed in leukemia,6 prostate carcinoma,6, 41 hepatocellular carcinoma,42 and lung
cancer.43 Knockdown of G9a inhibits prostate, lung, and leukemia cancer cell
growth.41, 43, 44 Moreover, G9a and/or GLP play a role in cocaine addiction,45, 46 mental
retardation,47 maintenance of HIV-1 (human immunodeficiency virus type 1) latency,48 and
stem cell function, maintenance, differentiation and reprogramming.49–54 In addition, GLP
has been implicated in Kleefstra syndrome,55, 56 a disorder affecting intellectual ability.
BIX01294 (1), the first selective inhibitor of G9a and GLP, was discovered via high
throughput screening (Figure 1).11 Optimization of this chemical series based on the
cocrystal structure of GLP in complex with inhibitor 157 led to the discovery of potent and
selective G9a/GLP inhibitors UNC0224 (2), UNC0321 (3), and E72 (4) (Figure 1).12–14
Further optimization of this quinazoline scaffold resulted in the discovery of the G9a and
GLP cellular chemical probe UNC0638 (5), which displays balanced in vitro potency,
aqueous solubility, and cell membrane permeability (Figure 1).15, 16 Inhibitor 5 is highly
selective for G9a and GLP over a broad range of epigenetic and non-epigenetic targets, and
exhibits robust on-target activities in cells and low cell toxicity.15 More recently, BRD9539
(6), a structurally distinct inhibitor of G9a, was reported (Figure 1).20 Although Inhibitor 5
is an excellent chemical probe for cell-based studies,54, 58 it is not suitable for animal studies
due to its poor in vivo pharmacokinetic (PK) properties.15 We therefore endeavored to
optimize the PK properties of the quinazoline series. Here we report the discovery of
UNC0642 (7), the first in vivo chemical probe of G9a and GLP. This inhibitor not only
displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity, but
also exhibits greatly improved in vivo PK properties as compared to inhibitor 5. We
describe: (1) the synthesis of novel compounds aimed at improving PK properties of this
series; (2) structure activity relationships (SAR) of these compounds in biochemical and
cell-based assays; (3) in vitro and in vivo PK properties of selected inhibitors; and (4)
further characterization of inhibitor 7 in a number of biochemical and cell-based studies
including mechanism of action, selectivity, and phenotypic effect studies.
Results and Discussion
Synthesis
We hypothesized that the 2-cyclohexyl group of inhibitor 5 could contribute to its poor
metabolic stability due to cytochrome P450 mediated oxidation of the cyclohexyl ring.
Because modifications to the 2-substituent of the quinazoline scaffold are well
tolerated,14, 16 we extensively explored this region and designed a number of novel analogs
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aimed at improving metabolic stability while maintaining high in vitro and cellular potency.
We also conducted limited exploration of the 4-amino and 7-aminoalkoxy regions.
We previously developed an efficient synthetic route for preparing 2-amino quinazolines,
which allows various 2-amino groups to be installed at the last step of the synthetic
sequence.16 Using this efficient route, we synthesized the 2-amino quinazolines 7, 13 – 17
from commercially available methyl 4-hydroxy-3-methoxybenzoate (8) in 9 steps in good
yields (Scheme 1 and Table 1). Briefly, compound 8 was reacted with 1-chloro-3-
iodopropane, followed by nitration, to afford the chloride 9. Substitution of the chloride with
pyrrolidine and subsequent reduction of the nitro group yielded the aniline 10. Urea
formation and subsequent ring closure afforded the intermediate 11, which was then
converted to the 2,4-dichloroquinazoline 12. Two consecutive displacement reactions
yielded the desired final products 7, 13 – 17. It is worth noting that 5 g of inhibitor 7 was
produced in 14.8% overall yield using this synthetic route. We also synthesized compounds
18 and 19, which contain a cyclopropyl group instead of an isopropyl group as the N-
capping of the upper piperidine moiety, following the same synthetic route.
Compound 22 which contains a tetrahydropyran-4-yl group at the 2-position was prepared
according to the synthetic route15 developed for synthesis of inhibitor 5 (Scheme 2). In brief,
the aniline 10 was reacted with tetrahydro-2H-pyran-4-carbonitrile to yield the cyclization
product 20, which was then converted to the 4-chloroquinazoline 21. Subsequent
displacement of the chloride with 1-isopropylpiperidin-4-amine afforded the desired product
22.
Finally, compound 26, which was designed to explore the 7-aminoalkoxy moiety, was
synthesized according to Scheme 3. Substitution of the chloride 9 with 4,4-
difluoropiperidine and subsequent reduction of the nitro group afforded the aniline 23,
which was reacted with cyclohexanecarbonitrile or tetrahydro-2H-pyran-4-carbonitrile to
yield the quinazoline 24. Similarly to synthesis of compound 22, the intermediate 24 was
converted to the 4-chloroquinazoline 25, which was subsequently converted to the desired
product 26.
SAR in a G9a Biochemical Assay
The synthesized compounds were evaluated in a radioactive biochemical assay which
measures the transfer of the tritiated methyl group from the cofactor 3H – S-adenosyl
methionine (SAM) to a peptide substrate catalyzed by G9a. IC50 values of these compounds
in this biochemical assay are summarized in Tables 1 – 3.
We were pleased to find that the 2-cyclohexyl group (5) can be replaced by a variety of 2-
substituents without a significant loss of potency (Table 1). In particular, compounds
possessing a 2-(4,4-difluoropiperidin-1-yl) (7), 2-(morpholin-4-yl) (13), 2-(piperidin-1-yl)
(16) or 2(azepan-1-yl) (17) maintained high in vitro potency (IC50 < 2.5 nM). Although
compounds 14, 15, and 22, which contain a 2-(1,1-dioxidethiomorpholin-4-yl), 2-(3,3,4,4-
tetrafluoropyrrolin-1yl) or 2-(tetrahydropyran-4-yl) group, were not as potent as compound
5, the in vitro potency of these inhibitors is still quite good (IC50 < 30 nM). These SAR
findings are consistent with our previous results,14, 16 further demonstrating that
modifications to the 2-amino region of the quinazoline scaffold are well tolerated.
For the N-capping of the upper piperidine moiety, we found that the isopropyl group can be
replaced by a cyclopropyl group (7 versus 18, and 14 versus 19) without a significant
change in potency (Table 2). Although we previously showed that a large N-capping group
such as cyclohexylmethyl is tolerated in this region,16 we thought that such a large lipophilic
group might increase metabolic liability, and therefore, did not explore this region further. In
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addition, we attempted to replace the 7-(3-(pyrrolidin-1-yl)propoxy) group with the 7-(3-
(4,4-difluoropiperidin-1-yl)propoxy) group (Table 3). To our surprise, this replacement
resulted in a complete loss of potency (5 versus 26a, and 22 versus 26b). Because a basic
nitrogen in this region is required for maintaining high in vitro potency and few
modifications are tolerated,14, 16 we did not further investigate this region.
Assessment of Functional Potency and Cell Toxicity
The inhibitors which displayed IC50 < 10 nM in the biochemical assay were next evaluated
in an H3K9me2 cell immunofluorescence in-cell western (ICW) assay for assessing their
cellular potency, and a standard resazurin (Alamar Blue) reduction assay for assessing their
cell toxicity. MDA-MB-231 cells were used in this study because this cell line possesses
robust H3K9me2 levels.
We were pleased to find that all 8 inhibitors exhibited good potency at reducing cellular
levels of H3K9me2 (IC50 = 100 – 600 nM), low cell toxicity (EC50 > 5,000 nM), and a good
separation of functional potency and cell toxicity with a ratio of toxicity to functional
potency (tox/function ratio, which is determined by dividing the EC50 value of the observed
toxicity by the IC50 value of the functional potency) > 45 (Table 4). In particular, inhibitors
7, 13, and 22 displayed high cellular potency and an excellent tox/function ratio (> 130),
similar to that of our G9a/GLP cellular chemical probe 5.
Assessment of in vitro and in vivo PK Properties
We next evaluated in vitro metabolic stability of selected inhibitors using mouse liver
microsomes. As shown in Table 5, inhibitors 7 and 13 displayed improved intrinsic
clearance (CLint) and half-life (T1/2) compared with inhibitor 5. Interestingly, inhibitor 15,
which possesses a 2-(3,3,4,4-tetrafluoropyrrolin-1yl) group, exhibited the best in vitro
metabolic stability although this inhibitor was significantly less potent than inhibitors 5, 7
and 13 (see Table 1). On the other hand, compounds 22 and 26, which contain a 2-
(tetrahydropyran-4-yl) group, displayed a significant decrease in metabolic stability.
Surprisingly, inhibitor 26 which has a 7-(3-(4,4-difluoropiperidin-1-yl)propoxy) group was
not only less potent than compound 22 which contains 7-(3-(pyrrolidin-1-yl)propoxy) group
(see Table 3), but also metabolically less stable compared with inhibitor 22. Taken together,
these results indicate that modifications aimed at preventing CYP450 mediated oxidation of
the 2-substituent of the quinazoline scaffold can lead to improved in vitro metabolic
stability.
On the basis of high in vitro and cellular potencies, low cell toxicity, and good in vitro
metabolic stability, we selected inhibitors 7 and 13 for evaluation of their in vivo PK
properties in male Swiss Albino mice. A single intraperitoneal (IP) injection (5 mg/kg) of
inhibitor 7 resulted in a plasma Cmax (maximum concentration) of 947 ng/mL, which is
more than 10-fold higher than that of inhibitor 5, and an AUC (area under the curve) of 1265
hr*ng/mL, which is also much higher than that of inhibitor 5 (Table 6). Similarly, a single 5
mg/kg IP injection of inhibitor 13 gave a much improved Cmax and AUC in plasma
compared with inhibitor 5. In addition, while inhibitor 7 displayed modest brain penetration
with a brain/plasma ratio of 0.33, inhibitor 13 exhibited increased CNS (central nervous
system) penetration with a brain/plasma ratio of 0.68. These encouraging PK results suggest
that inhibitors 7 and 13 could be used for animal studies and 13 might be suitable for studies
to explore the role of G9a/GLP in the CNS. These results also indicate that appropriate
modifications to the 2-substituent of the quinazoline scaffold can improve in vivo PK
properties, thus validating our probe design hypothesis.
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Further Characterization of Inhibitor 7
We next carried out a number of probe characterization studies. First, we studied the MOA
(mechanism of action) of inhibitor 7 by determining Michaelis-Menten kinetic parameters
associated with both the peptide substrate and cofactor SAM. As shown in Figure 2, the
apparent Km of the peptide (Kmapp) increased linearly with inhibitor concentration, whereas
the Kmapp of SAM remained constant in the presence of increasing concentrations of the
inhibitor. These results indicate that inhibitor 7 is competitive with the peptide substrate and
non-competitive with the cofactor SAM, the same MOA as inhibitor 5.15 The Ki of inhibitor
7 was determined to be 3.7 ± 1 nM (n = 3).
We next determined the selectivity of inhibitor 7 versus 15 methyltransferases and a broad
range of non-epigenetic targets. We expected this inhibitor to be highly potent for GLP on
the basis of the high sequence identity between G9a and GLP.10 Indeed, inhibitor 7
displayed high in vitro potency for GLP (IC50 < 2.5 nM), similar to G9a (Figure 3A, Table
1). This result is consistent with the selectivity profile of our cellular chemical probe 5.15
Importantly, inhibitor 7 was more than 20,000-fold selective for G9a and GLP over 13 other
methyltransferases (IC50 > 50,000 nM) and more than 2,000-fold selective over PRC2 –
EZH2 (polycomb repressive complex 2 – enhancer of zeste homolog 2, IC50 > 5,000 nM)
(Figure 3B). In addition, inhibitor 7 showed no appreciable inhibition (less than 20%
inhibition at 10,000 nM) against a panel of 50 representative kinases (Table S1). We also
tested inhibitor 7 against 44 GPCRs (G protein-coupled receptors), transporters, and ion
channels in the National Institute of Mental Health – Psychoactive Drug Screen Program
Selectivity Panel. This inhibitor was found to show less than 50% inhibition at 1,000 nM
against 39 targets and > 50% inhibition at 1,000 nM against 5 targets in the panel (Table
S2). Ki values for each of the 5 interacting targets were then determined in radioligand
binding assays. Inhibitor 7 had Ki values of 4,500 nM, > 10,000 nM, 45 nM, > 10,000 nM,
and 900 nM for α1D, α2C, histamine H3, µ opioid, and σ2 receptors, respectively (Table S3).
Therefore, with the exception of the histamine H3 receptor, inhibitor 7 was more than 300-
fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion
channels.
In addition to MDA-MB-231 cells, we assessed functional potency and cell toxicity of
inhibitor 7 in several other cell lines (Table 7). Inhibitor 7 displayed high potency (IC50 <
150 nM) in reducing cellular levels of H3K9me2, low cell toxicity (EC50 > 3,000 nM),
resulting in a good separation of functional potency and cell toxicity with a tox/function
ratio of > 45 in U2OS, PC3, and PANC-1 cells. In particular, this inhibitor exhibited
excellent potency (IC50 = 40 nM) in PANC-1 cells with a good tox/function ratio of 88.
Lastly, we evaluated effects of inhibitor 7 on clonogenicity in PANC-1 and MDA-MB-231
cells. As shown in Figure 4, inhibitor 7 reduced clonogenicity in PANC-1 cells in a
concentration-dependent manner while it had no effect on clonogenicity in MDA-MB-231
cells. These results are consistent with the previous report that PANC-1 cells are highly
sensitive to G9a inhibitors20 and our previous finding that MDA-MB-231 cells are
insensitive to G9a/GLP inhibitors.15 These observations suggest that pharmacological
inhibition of G9a and GLP can have differential phenotypic effects depending on the cell
type and/or disease setting.
Conclusions
We designed, synthesized, and biologically evaluated a set of novel compounds aimed at
improving the in vivo PK properties of our previously reported G9a/GLP cellular chemical
probe 5. From these studies, we discovered inhibitor 7, which is the first in vivo chemical
probe of G9a and GLP. This inhibitor: (1) displayed high in vitro potency for G9a and GLP
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(IC50 < 2.5 nM); (2) was > 2,000-fold selective for G9a and GLP over PRC2 – EZH2 and >
20,000-fold selective over 13 other methyltransferases; (3) was > 300-fold selective for G9a
and GLP over a broad range of kinases, GPCRs, ion channels, and transporters with the
exception of the histamine H3 receptor; (4) was competitive with the peptide substrate and
non-competitive with the cofactor SAM; (5) exhibited high potency at reducing the
H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell
toxicity in a number of cell lines; (6) reduced clonogenicity in PANC-1 cells, a pancreatic
carcinoma cell line; and (7) importantly, displayed improved in vitro and in vivo PK
properties. We also discovered inhibitor 13, which had better brain penetration than inhibitor
7 and might be suitable for CNS studies. These two inhibitors are valuable additions to our
G9a/GLP inhibitor toolbox, and are freely available to the research community for
investigating the role of G9a and GLP in health and disease.
Experimental Section
Chemistry general procedures
HPLC spectra for all compounds were acquired using an Agilent 6110 Series system with
UV detector set to 254 nm. Samples were injected (5 µL) onto an Agilent Eclipse Plus 4.6 ×
50 mm, 1.8 µM, C18 column at room temperature. A linear gradient from 10% to 100% B
(MeOH + 0.1% acetic acid) in 5.0 min was followed by pumping 100% B for another 2
minutes with A being H2O + 0.1% acetic acid. The flow rate was 1.0 mL/min. Mass spectra
(MS) data were acquired in positive ion mode using an Agilent 6110 single quadrupole mass
spectrometer with an electrospray ionization (ESI) source. High-resolution (positive ion)
mass spectrum (HRMS) for compound 7 and 13 were acquired using a Thermo LTqFT mass
spectrometer under FT control at 100,000 resolution. Nuclear Magnetic Resonance (NMR)
spectra were recorded at Varian Mercury spectrometer with 400 MHz for proton (1H NMR),
100 MHz for carbon (13C NMR) and 376 MHz for Fluorine (19F NMR). Chemical shifts are
reported in ppm (δ). Preparative HPLC was performed on Agilent Prep 1200 series with UV
detector set to 220 nm. Samples were injected onto a Phenomenex Luna 75 × 30 mm, 5 µM,
C18 column at room temperature. The flow rate was 30 mL/min. A linear gradient was used
with 10% of MeOH (A) in 0.1 % TFA in H2O (B) to 100% of MeOH (A). HPLC was used
to establish the purity of target compounds. All compounds had > 95% purity using the
HPLC methods described above.
Synthesis of compound 5 was reported previously.15
2-(4,4-Difluoropiperidin-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-
(pyrrolidin-1-yl)propoxy)quinazolin-4-amine (7)—A mixture of compound 12 (0.72
g, 2.02 mmol) (prepared from commercially available methyl 3-methoxyl-4-hydroxy
benzoate (8) according to the procedures described previously15), 1-isopropylpiperidin-4-
amine·2TFA salt (2.3 g, 6.06 mmol) (this amine and other non-commercially available
amines were prepared according to previously reported procedures59), and DIEA (0.67 mL,
4.04 mmol) in THF (10 mL) was stirred overnight at rt. After concentration in vacuo, the
crude product was purified by silica gel chromatography (0 – 20% MeOH (1% NH3)/
CH2Cl2) to afford the desired product 2-chloro-N-(1-isopropylpiperidin-4-yl)-6-methoxyl-7-
(3-(pyrrolidin-1-yl)propoxyl) quinazolin-4-amine as a yellow solid (0.88 g, 94% yield). 1H
NMR (400 MHz, CDCl3) δ 7.12 (s, 1H), 6.78 (s, 1H), 5.36 (d, J = 7.7 Hz, 1H), 4.31 – 4.20
(m, 1H), 4.17 (t, J = 6.7 Hz, 2H), 3.96 (s, 3H), 2.90 (d, J = 11.9 Hz, 2H), 2.84 – 2.73 (m,
1H), 2.67 – 2.59 (m, 2H), 2.57 – 2.46 (m, 4H), 2.45 – 2.34 (m, 2H), 2.22 – 2.05 (m, 4H),
1.84 – 1.74 (m, 4H), 1.07 (d, J = 6.6 Hz, 6H). MS (ESI): 462 [M + H]+. A mixture of this
intermediate (55 mg, 0.12 mmol), 4,4-difluoropiperidine hydrochloride salt (37 mg, 0.24
mmol), and TFA (55 mg, 0.48 mmol) in i-PrOH (0.25 mL) was heated by microwave
irradiation at 160 °C for 15 min in a sealed tube. After concentration in vacuo the crude
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product was purified by preparative HPLC with a gradient from 10% MeOH (A) in 0.1%
TFA in H2O (B) to 100% of MeOH (A). The resulting product was basified with saturated
aq. NaHCO3 and extracted with CH2Cl2 to afford the title compound 7 as a white solid (52
mg, 80% yield). 1H NMR (400 MHz, CDCl3) δ 6.91 (s, 1H), 6.70 (s, 1H), 4.97 (d, J = 7.2
Hz, 1H), 4.18 (t, J = 6.8 Hz, 2H), 4.13 – 4.03 (m, 1H), 4.02 – 3.94 (m, 4H), 3.92 (s, 3H),
2.97 – 2.86 (m, 2H), 2.83 – 2.72 (m, 1H), 2.63 (t, J = 7.2 Hz, 2H), 2.58 – 2.46 (m, 4H), 2.34
(td, J = 11.6, 2.2 Hz, 2H), 2.21 – 2.14 (m, 2H), 2.14 – 2.07 (m, 2H), 2.07 – 1.94 (m, 4H),
1.82 – 1.74 (m, 4H), 1.58 (ddd, J = 14.9, 11.8, 3.7 Hz, 2H), 1.08 (d, J = 6.5 Hz, 6H). 19F
NMR (376 MHz, CDCl3) δ −96.10 – −97.04 (m, 2F). 13C NMR (100 MHz, CDCl3) δ
158.49, 158.32, 154.23, 149.33, 146.00, 122.95 (t, J = 241.4 Hz), 107.18, 103.18, 101.34,
67.47, 56.69, 54.59, 54.28 (two carbons), 53.01 (two carbons), 48.77, 47.85, 41.25 (t, J = 4.9
Hz) (two carbons), 34.00 (t, J = 22.4 Hz) (two carbons), 32.72 (two carbons), 28.62 (two
carbons), 23.57, 18.58 (two carbons). HPLC: 100%; tR 2.37 min. MS (ESI): 547 [M + H]+.
HRMS (ESI) calcd for C29H44F2N6O2Na [M + Na]+: 569.3392. Found: 569.3384.
N-(1-Isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-4-amine (13)—The procedure used for preparation of
compound 7 was followed for synthesis of compound 13. The title compound 13 was
obtained as a white solid (55 mg, 78% yield). 1H NMR (400 MHz, CDCl3) δ 6.90 (s, 1H),
6.72 (s, 1H), 5.04 (d, J = 7.3 Hz, 1H), 4.15 (t, J = 6.8 Hz, 2H), 4.12 – 4.02 (m, 1H), 3.89 (s,
3H), 3.85 – 3.72 (m, 8H), 2.95 – 2.85 (m, 2H), 2.81 – 2.71 (m, 1H), 2.61 (t, J = 7.2 Hz, 2H),
2.55 – 2.44 (m, 4H), 2.32 (td, J = 11.6, 2.1 Hz, 2H), 2.21 – 2.12 (m, 2H), 2.12 – 2.02 (m,
2H), 1.82 – 1.71 (m, 4H), 1.57 (ddd, J = 14.9, 11.8, 3.7 Hz, 2H), 1.06 (d, J = 6.6 Hz,
6H). 13C NMR (100 MHz, CDCl3) δ 159.06, 158.35, 154.21, 149.23, 145.96, 107.19,
103.38, 101.40, 67.47, 67.23 (two carbons), 56.71, 54.63, 54.29 (two carbons), 53.04 (two
carbons), 48.68, 47.90, 44.80 (two carbons), 32.71 (two carbons), 28.63 (two carbons),
23.59, 18.58 (two carbons). HPLC: 100%; tR 2.19 min. MS (ESI): 513 [M + H]+. HRMS
(ESI) calcd for C28H45N6O3 [M + H]+: 513.3553. Found: 513.3550.
4-(4-((1-Isopropylpiperidin-4-yl)amino)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-2-yl)thiomorpholine 1,1-dioxide (14)—The procedure used
for preparation of compound 7 was followed for synthesis of compound 14. The title
compound 14 was obtained as a white solid (47 mg, 81% yield). 1H NMR (400 MHz,
CDCl3) δ 6.88 (s, 1H), 6.79 (s, 1H), 5.32 (d, J = 7.3 Hz, 1H), 4.42 – 4.24 (m, 4H), 4.14 (t, J
= 6.8 Hz, 2H), 4.07 – 3.94 (m, 1H), 3.88 (s, 3H), 3.09 – 2.96 (m, 4H), 2.93 – 2.82 (m, 2H),
2.79 – 2.68 (m, 1H), 2.59 (t, J = 7.3 Hz, 2H), 2.55 – 2.41 (m, 4H), 2.34 – 2.22 (m, 2H), 2.14
– 2.01 (m, 4H), 1.81 – 1.68 (m, 4H), 1.58 (ddd, J = 14.9, 12.0, 3.7 Hz, 2H), 1.03 (d, J = 6.6
Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 158.69, 157.01, 154.25, 148.86, 146.47, 107.18,
103.50, 101.25, 67.40, 56.61, 54.56, 54.19 (two carbons), 52.89 (two carbons), 51.55 (two
carbons), 48.80, 47.74, 42.96 (two carbons), 32.46 (two carbons), 28.46 (two carbons),
23.49, 18.44 (two carbons). HPLC: 98%; tR 1.97 min. MS (ESI): 561 [M + H]+.
N-(1-Isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-2-
(3,3,4,4-tetrafluoropyrrolidin-1-yl)quinazolin-4-amine (15)—The procedure used for
preparation of compound 7 was followed for synthesis of compound 15. The title compound
15 was obtained as a white solid (46 mg, 75% yield). 1H NMR (400 MHz, CDCl3) δ 6.94 (s,
1H), 6.73 (s, 1H), 5.12 (d, J = 7.3 Hz, 1H), 4.25 – 4.01 (m, 7H), 3.91 (s, 3H), 2.98 – 2.85 (m,
2H), 2.83 – 2.71 (m, 1H), 2.66 – 2.58 (m, 2H), 2.56 – 2.45 (m, 4H), 2.34 (td, J = 11.6, 2.1
Hz, 2H), 2.20 – 2.04 (m, 4H), 1.84 – 1.71 (m, 4H), 1.58 (qd, J = 11.8, 3.7 Hz, 2H), 1.07 (d, J
= 6.6 Hz, 6H). 19F NMR (376 MHz, CDCl3) δ −77.18. 13C NMR (100 MHz, CDCl3) δ
158.49, 156.76, 154.46, 148.92, 146.37, 118.61 (m, two carbons), 107.17, 103.61, 101.22,
67.59, 56.70, 54.65, 54.32 (two carbons), 53.02 (two carbons), 50.76 (t, J = 28.8 Hz) (two
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carbons), 48.90, 47.87, 32.74 (two carbons), 28.62 (two carbons), 23.61, 18.57 (two
carbons). HPLC: 99%; tR 2.49 min. MS (ESI): 569 [M + H]+ .
Compounds 16 and 17 were synthesized according to previously reported procedures.16
N-(1-Cyclopropylpiperidin-4-yl)-2-(4,4-difluoropiperidin-1-yl)-6-methoxy-7-(3-
(pyrrolidin-1-yl)propoxy)quinazolin-4-amine (18)—The procedure used for
preparation of compound 7 was followed for synthesis of compound 18. The title compound
18 was obtained as a yellowish solid (47 mg, 82% yield). 1H NMR (400 MHz, CDCl3) δ
6.90 (s, 1H), 6.73 (s, 1H), 5.08 (d, J = 7.2 Hz, 1H), 4.21 – 4.05 (m, 3H), 4.02 – 3.93 (m, 4H),
3.88 (s, 3H), 3.08 – 2.98 (m, 2H), 2.68 – 2.57 (m, 2H), 2.57 – 2.46 (m, 4H), 2.38 (td, J =
11.7, 2.2 Hz, 2H), 2.16 – 2.06 (m, 4H), 2.06 – 1.92 (m, 4H), 1.82 – 1.72 (m, 4H), 1.65 –
1.59 (m, 1H), 1.52 (ddd, J = 14.9, 12.2, 3.8 Hz, 2H), 0.49 – 0.43 (m, 2H), 0.43 – 0.37 (m,
2H). 13C NMR (100 MHz, CDCl3) δ 158.49, 158.29, 154.18, 149.30, 145.97, 122.93 (t, J =
4.8 Hz), 107.17, 103.19, 101.34, 67.39, 56.66, 54.24 (two carbons), 52.99 (two carbons),
52.81, 48.54, 41.24 (t, J = 241.4 Hz) (two carbons), 38.61, 33.99 (t, J = 22.4 Hz) (two
carbons), 32.21 (two carbons), 28.50 (two carbons), 23.56, 6.15 (two carbons). HPLC: 99%;
tR 2.45 min. MS (ESI): 545 [M + H]+.
4-(4-((1-Cyclopropylpiperidin-4-yl)amino)-6-methoxy-7-(3-(pyrrolidin-1-
yl)propoxy)quinazolin-2-yl)thiomorpholine 1,1-dioxide (19)—The procedure used
for preparation of compound 7 was followed for synthesis of compound 19. The title
compound 19 was obtained as a yellowish solid (42 mg, 76% yield). 1H NMR (400 MHz,
CDCl3) δ 6.90 (s, 1H), 6.76 (s, 1H), 5.21 (d, J = 7.3 Hz, 1H), 4.44 – 4.26 (m, 4H), 4.16 (t, J
= 6.8 Hz, 2H), 4.13 – 4.01 (m, 1H), 3.90 (s, 3H), 3.10 – 2.96 (m, 6H), 2.66 – 2.58 (m, 2H),
2.57 – 2.46 (m, 4H), 2.43 – 2.29 (m, 2H), 2.15 – 2.01 (m, 4H), 1.83 – 1.69 (m, 4H), 1.66 –
1.48 (m, 3H), 0.49 – 0.43 (m, 2H), 0.42 – 0.36 (m, 2H). 13C NMR (100 MHz, CDCl3) δ
158.72, 157.06, 154.35, 148.94, 146.57, 107.28, 103.50, 101.17, 67.45, 56.68, 54.25 (two
carbons), 52.96 (two carbons), 52.73, 51.61 (two carbons), 48.67, 43.01 (two carbons),
38.57, 32.17 (two carbons), 28.49 (two carbons), 23.55, 6.17 (two carbons). HPLC: 98%; tR
1.97 min. MS (ESI): 559 [M + H]+.
4-Chloro-6-methoxy-2-(phosphinan-4-yl)-7-(3-(pyrrolidin-1-
yl)propoxy)quinazoline (21)—In a sealed tube, a mixture of compound 10 (0.61 g, 2.0
mmol) (prepared according to the procedures described previously15), tetrahydro-2H-
pyran-4-carbonitrile (2.2 g, 19.8 mmol) and HCl (4 N solution in dioxane, 8 mL, 32 mmol)
was stirred overnight at 100 °C. The reaction mixture was poured into water and neutralized
with NaHCO3. The resulting precipitate was collected and dried to provide the desired crude
product 20 (0.58 g, 1.5 mmol). A mixture of this crude compound 20 (0.58 g, 1.5 mmol) and
N,N–diethylaniline (0.24 mL, 1.5 mmol) in POCl3 (10 mL) was heated at reflux for 4h. The
reaction mixture was concentrated in vacuo and saturated aq. NaHCO3 (15 mL) was added.
The resulting mixture was extracted with chloroform (15 mL × 3). The combined organic
layers were dried, concentrated and purified by flash column chromatography on silica gel
(0 – 10% MeOH / CH2Cl2) to afford the title compound 21 as a yellow solid (0.38 g, 48%
over two steps). 1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 7.23 (s, 1H), 4.22 (t, J = 6.4
Hz, 2H), 4.07–4.02 (m, 2H), 3.96 (s, 3H), 3.50 (td, J = 11.2, 2.8 Hz, 2H), 3.12–3.06 (m, 1H),
2.65 (t, J = 7.2 Hz, 2H), 2.55–2.53 (m, 4H), 2.15–2.09 (m, 2H), 2.05–1.92 (m, 4H), 1.77–
1.74 (m, 4H).
N-(1-Isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-2-
(tetrahydro-2H-pyran-4-yl)quinazolin-4-amine (22)—A suspension of compound 21
(95 mg, 0.23 mmol), 1-isopropylpiperidin-4-amine 2TFA salt (0.24 g, 0.72 mmol), and
K2CO3 (0.33 g, 2.4 mmol) in DMF (3.0 mL) was stirred overnight at 60 °C. The reaction
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mixture was cooled to rt, water (10 mL) was added and the mixture was extracted with
CH2Cl2. The combined organic layers were concentrated and purified by preparative HPLC.
The resulting product was basified with saturated aq. NaHCO3 and extracted with CH2Cl2 to
afford the desired product 22 as a white solid (91 mg, 78% yield). 1H NMR (400 MHz,
CDCl3) δ 7.14 (s, 1H), 6.81 (s, 1H), 5.20 (d, J = 7.2 Hz, 1H), 4.26 – 4.12 (m, 3H), 4.12 –
4.02 (m, 2H), 3.91 (s, 3H), 3.54 (td, J = 11.9, 1.9 Hz, 2H), 3.00 – 2.85 (m, 3H), 2.83 – 2.71
(m, 1H), 2.65 – 2.55 (m, 2H), 2.55 – 2.42 (m, 4H), 2.42 – 2.31 (m, 2H), 2.25 – 2.14 (m, 2H),
2.13 – 1.97 (m, 4H), 1.93 – 1.83 (m, 2H), 1.81 – 1.68 (m, 4H), 1.56 (ddd, J = 23.4, 11.9, 3.7
Hz, 2H), 1.06 (d, J = 6.6 Hz, 6H). 13C NMR (100 MHz, CDCl3) δ 167.45, 158.00, 153.85,
148.68, 147.34, 108.53, 106.83, 100.04, 68.19 (two carbons), 67.64, 56.50, 54.63, 54.28
(two carbons), 52.95 (two carbons), 48.74, 47.85, 44.82, 32.76 (two carbons), 31.63 (two
carbons), 28.52 (two carbons), 23.58, 18.56 (two carbons). HPLC: 98%; tR 2.31 min. MS
(ESI): 512 [M + H]+.
Methyl 2-amino-4-(3-(4,4-difluoropiperidin-1-yl)propoxy)-5-methoxybenzoate
(23)—The procedure used for preparation of compound 10 was followed for synthesis of
compound 23. The title compound 23 was obtained as a yellow oil (2.1 g, 49% yield over 2
steps). 1H NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 6.17 (s, 1H), 5.58 (br, 2H), 4.10 (t, J =
6.4 Hz, 2H), 3.85 (s, 3H), 3.79 (s, 3H), 3.17–2.81 (m, 6H), 2.48–2.19 (m, 6H).
4-Chloro-2-cyclohexyl-7-(3-(4,4-difluoropiperidin-1-yl)propoxy)-6-
methoxyquinazoline (25a)—In a sealed tube, a mixture of compound 23 (1.1 g, 3.0
mmol), cyclohexanecarbonitrile (3.3 g, 30.0 mmol) and HCl (4 N solution in dioxane, 15
mL, 60 mmol) was stirred overnight at 100 °C. The reaction mixture was poured into water
and neutralized with NaHCO3. The resulting precipitate was collected and dried to provide
the intermediate 24a (1.0 g, 2.3 mmol). A mixture of the crude compound 24a (1.0 g, 2.3
mmol) and N,N–diethylaniline (0.37 mL, 2.3 mmol) in POCl3 (20 mL) was heated at reflux
for 4 h. The reaction mixture was concentrated in vacuo and saturated aq. NaHCO3 (30 mL)
was added. The resulting mixture was extracted with chloroform (30 mL × 3). The
combined organic layers were dried, concentrated and purified by flash column
chromatography on silica gel (0 – 10% MeOH / CH2Cl2) to afford the 25a as a yellowish
solid (0.72 g, 53% yield over 2 steps). 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 7.28 (s,
1H), 4.28 (t, J = 6 Hz, 2H), 4.02 (s, 3H), 2.93 (tt, J = 11.6, 3.6 Hz, 1H), 2.83–2.41 (m, 6H),
2.27–1.96 (m, 6H), 1.93–1.84 (m, 4H), 1.81–1.64 (m, 3H), 1.51–1.29 (m, 3H).
7-(3-(4,4-Difluoropiperidin-1-yl)propoxy)-N-(1-isopropylpiperidin-4-yl)-6-
methoxy-2-cyclohexyl quinazolin-4-amine (26a)—The procedure used for
preparation of compound 5 was then followed for synthesis of compound 26a. The title
compound 26a was obtained as a yellowish solid from intermediate 25a (46 mg, 77%
yield). 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 6.81 (s, 1H), 5.18 (d, J = 7.2 Hz, 1H),
4.24 – 4.13 (m, 3H), 4.13 – 4.02 (m, 2H), 3.90 (s, 3H), 2.90 (d, J = 12 Hz, 2H), 2.80–2.66
(m, 2H), 2.55–2.50 (m, 6H), 2.36 (td, J = 11.6, 2 Hz, 2H), 2.22–2.19 (m, 2H), 2.05–1.90 (m,
8H), 1.85–1.81 (m, 2H), 1.73–1.51 (m, 5H), 1.45–1.27 (m, 3H), 1.06 (d, J = 6.0 Hz,
6H). 13C NMR (100 MHz, CDCl3) δ 169.42, 157.82, 153.44, 148.25, 147.26, 122.06 (t, J =
240 Hz), 108.44, 106.68, 99.89, 67.11, 56.28, 54.48, 53.94 (two carbons), 49.99 (t, J = 5 Hz)
(two carbons), 48.56, 47.88, 47.74, 33.99 (t, J = 23 Hz) (two carbons), 33.76, 32.67 (two
carbons), 26.61 (two carbons), 26.39 (two carbons), 26.21, 18.49 (two carbons). HPLC:
97%; tR 2.74 min. MS (ESI): 560 [M + H]+.
4-Chloro-7-(3-(4,4-difluoropiperidin-1-yl)propoxy)-6-methoxy-2-(piperidin-1-
yl)quinazoline (25b)—The procedure used for preparation of compound 25a was then
followed for synthesis of compound 25b. The title compound 25b was obtained as a
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yellowish solid (0.39 g, 49% yield over 2 steps). 1H NMR (400 MHz, CDCl3) δ 7.36 (s, 1H),
7.29 (s, 1H), 4.29 (t, J = 6 Hz, 2H), 4.13–4.09 (m, 2H), 4.03 (s, 3H), 3.57 (td, J = 11.6, 2.4
Hz, 2H), 3.21–3.14 (m, 1H), 2.74–2.43 (m, 6H), 2.16–1.96 (m, 10H).
7-(3-(4,4-Difluoropiperidin-1-yl)propoxy)-N-(1-isopropylpiperidin-4-yl)-6-
methoxy-2-(tetrahydro-2H-pyran-4-yl)quinazolin-4-amine (26b)—The procedure
used for preparation of compound 26a was followed for synthesis of compound 26b. The
title compound 26b was obtained as a yellowish solid from compound 25b (48 mg, 75%
yield). 1H NMR (400 MHz, CDCl3) δ 7.15 (s, 1H), 6.80 (s, 1H), 5.16 (d, J = 7.2 Hz, 1H),
4.28 – 4.13 (m, 3H), 4.13 – 4.02 (m, 2H), 3.93 (s, 3H), 3.55 (td, J = 11.9, 2.0 Hz, 2H), 3.01 –
2.85 (m, 3H), 2.83 – 2.71 (m, 1H), 2.63 – 2.47 (m, 6H), 2.36 (td, J = 11.6, 2.2 Hz, 2H), 2.26
– 2.14 (m, 2H), 2.14 – 1.82 (m, 10H), 1.56 (qd, J = 11.8, 3.7 Hz, 2H), 1.07 (d, J = 6.6 Hz,
6H). 13C NMR (100 MHz, CDCl3) δ 167.56, 158.00, 153.75, 148.65, 147.32, 122.17 (t, J =
241.4 Hz), 108.53, 106.88, 99.95, 68.20 (two carbons), 67.29, 56.47, 54.63, 54.08 (two
carbons), 50.15 (t, J = 5.4 Hz) (two carbons), 48.78, 47.86, 44.86, 34.13 (t, J = 22.9 Hz)
(two carbons), 32.82 (two carbons), 31.64 (two carbons), 26.75, 18.59 (two carbons). HPLC:
97%; tR 1.63 min. MS (ESI): 562 [M + H]+ .
Methyltransferase activity assays
Methyltransferase activity assays were performed by monitoring the incorporation of
tritium-labeled methyl group to biotinylated peptide substrates using Scintillation Proximity
Assay (SPA) for G9a, GLP, PRMT3, SETD7, SETDB1, SETD8, SUV420H1, SUV420H2,
SUV39H2, PRC2 trimeric complex (EZH2:EED:SUZ12), MLL1 tetrameric complex
(MLL:WDR5:RbBP5:ASH2L), PRMT5-MEP50 complex and SMYD2. Assay components
for all assays are summarized in Table S4. The reaction buffer for SMYD2 and SMYD3 was
50 mM Tris pH 9.0, 5 mM DTT, 0.01%TritonX-100; for G9a, GLP and SUV39H2 was 25
mM potassium phosphate pH 8.0, 1 mM EDTA, 2 mM MgCl2 and 0.01% Triton X-100; and
for other HMTs 20 mM Tris pH 8.0, 5 mM DTT, 0.01% TritonX-100. To stop the enzymatic
reactions, 10 µL of 7.5 M guanidine hydrochloride was added, followed by 180 µL of buffer,
mixed and transferred to a 96-well FlashPlate (Cat.# SMP103; Perkin Elmer;
www.perkinelmer.com). After mixing, the reaction mixtures were incubated and the CPM
counts were measured using Topcount plate reader (Perkin Elmer, www.perkinelmer.com).
The CPM counts in the absence of compound for each data set were defined as 100%
activity. In the absence of the enzyme, the CPM counts in each data set were defined as
background (0%). IC50 values were determined using compound concentrations ranging
from 100 nM to 100 µM. The IC50 values were determined using SigmaPlot software.
For DNMT1, the assay was performed as described above using hemimethylated dsDNA as
a substrate. The dsDNA substrate was prepared by annealing two complementary strands
(biotintlated forward strand: B-GAGCCCGTAAGCCCGTTCAGGTCG and reverse strand:
CGACCTGAACGGGCTTACGGGCTC), synthesized by Eurofins MWG Operon. Reaction
buffer was 20 mM Tris-HCl, pH 8.0, 5mM DTT, 0.01% Triton X-100.
Methyltransferase activity assays for DOT1L and SMYD3 were performed using Filter-
plates (Millipore; cat.# MSFBN6B10; www.millipore.com). Reaction mixtures in 20 mM
Tris-HCl, pH 8.0, 5 mM DTT, 2 mM MgCl2 and 0.01% Triton X-100 were incubated at
room temperature for 1h, 100 µL 10% TCA was added, mixed and transferred to filter-plate.
Plates were centrifuged at 2000 rpm for 2 min followed by 2 additional 10% TCA wash and
one ethanol wash (180 µL) followed by centrifugation. Plates were dried and 100 µL
MicroO was added and centrifuged. 70 µL MicroO was added and CPM were measured
using Topcount plate reader.
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Ki determination for inhibitor 7
A competition between inhibitor 7 and the peptide was measured using microfluidic
capillary electrophoresis to monitor the methylation status of peptide substrates. Reactions
(15 µL) were set up in Nunc polypropylene shallow low volume 384-well microplates
containing a 5 µL spot of the compound in 1.5% DMSO and 1X Assay Buffer (20 mM Tris-
HCl pH = 8, 25 mM NaCl, 0.05% Tween 20 and 2 mM DTT) and a 5 µL spot of the peptide
substrate60 in 1X Assay Buffer arrayed in an 6 × 8 grid pattern. Inhibitor 7 was titrated from
20 nM to 1.76 nM using 1.5-fold dilution and peptide was titrated from 50 µM to 1.6 µM
using 2-fold dilution scheme. A total of 4 grids for each assay time point were set up. 5 µL
of G9a and SAM cocktail were added to initiate the reaction (to final concentration of 5 nM
and 200 µM, respectively). The reactions were allowed to proceed for 20, 30, 40 and 60 min
at 25 °C, and 10 µL of Endo-LysC (40 pg/µL) and inhibitor 5 (10 µM) mix were added to
stop the reaction and digest remaining unmethylated peptide. After 1 h, peptide
concentrations over 10 µM were diluted to 10 µM in 1X reaction buffer (to avoid saturation
of the optics) and the plate was read on a Caliper Life Sciences EZR II, using upstream
voltage = −500 V, downstream voltage = −1200 V and pressure = 1.5 psi. Pre-digested
peptide was used as the marker. The steady-state velocity was analyzed by linear regression
of the peptide methylation versus time and plotted to determine Michaelis-Menten kinetics
(GraphPad Prism 5.0). Km and kcat values were plotted to determine the relationship of the
peptide and the inhibitor on enzyme kinetics. The Ki value is an average of 3 replicates ±
SD.
Competition of inhibitor 7 with SAM
This assay was performed as described previously.15
Kinase selectivity assays
Selectivity of inhibitor 7 against a panel of 50 kinases was conducted using a standard off-
chip mobility shift assay technology. The full list of the 50 kinases is included in Table S1.
GPCRs, ion channels, and transporters selectivity assays
Selectivity of inhibitor 7 against 44 GPCRs, ion channels, and transporters was performed in
standard radioligand binding assays. The full list of the 44 targets is included in Table S2.
Cellular Assays
MDA-MB-231, PC3, and U2OS cells were cultured in RPMI with 10% FBS, PANC-1 cells
in DMEM with 10% FBS. Cells were treated with inhibitors for 48 h. Cell viability assays
were performed by incubating cells with 0.1 mg/mL of resazurin (Sigma) for 3 – 4 h.
Resazurin reduction was monitored with 544 nm excitation, measuring fluorescence at 590
nm. In-cell western assay was performed as described previously.15
For clonogenicity assays, PANC-1 and MDA-MB-231 cells were cultured in the presence of
the inhibitor for 2 days and seeded in 12 well plates at the density of 200 – 300 cells per well
in triplicates. The cells were cultured for 2 weeks until colonies were visible. Cell media and
the inhibitor were changed every 3 – 4 days. Colonies were stained in 1% methylene blue in
50% methanol and counted. The experiments repeated twice with consistent results.
Colonies were scored using Clono-Counter.
In vitro metabolic stability studies
Standard in vitro metabolic stability studies were conducted. Compound concentrations were
measured after 0, 5, 15, 30, and 45 min incubation of test compounds with mouse liver
microsomes.
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Standard PK studies were performed using male Swiss albino mice. Plasma and brain
concentrations were measured at 0.08, 0.25, 0.5, 1, 2, 4, 8, and 24 h following a single IP
injection of inhibitor 7 or 13 at 5 mg/kg. The compound concentration at each time point in
plasma or brain is the average value from 3 test animals.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
H3K9me2 dimethylation of histone H3 lysine 9
PK pharmacokinetic
PKMTs protein lysine methyltransferases
HMTs histone methyltransferases
PRMT protein arginine methyltransferase
KMT1C lysine methyltransferase 1C
EHMT2 euchromatic histone methyltransferase 2
KMT1D lysine methyltransferase 1D
EHMT1 euchromatic histone methyltransferase 1
H3K9 histone H3 lysine 9
SET suppressor of variegation 3–9, enhancer of zeste, and trithorax
HIV-1 human immunodeficiency virus type 1









AUC area under the curve
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MOA mechanism of action
Kmapp apparent Km
PRC2 – EZH2 polycomb repressive complex 2 – enhancer of zeste homolog 2
GPCRs G protein-coupled receptors
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Known small-molecule inhibitors of G9a/GLP.11–15, 20
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MOA studies of inhibitor 7. (A) and (B) The competition of inhibitor 7 and the H3K9
peptide indicates that 7 is competitive with the peptide substrate. The Kmapp of the peptide
increased linearly with compound concentration. (C) and (D) The competition with the
cofactor SAM reveals that inhibitor 7 is non-competitive with the cofactor. The Kmapp of
SAM were not affected by inhibitor concentration.
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Selectivity of inhibitor 7 versus 15 other methyltransferases.
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Inhibitor 7 affects clonogenicity of PANC-1 cells but not MDA-MB-231 cells. (A) PANC-1
cell colonies after 2 weeks of growth in the presence of inhibitor 7 at 0, 0.5 or 1 µM. (B)
Graphical representation of data in (A). (C) MDA-MB-231 cell colonies after 2 weeks of
growth in the presence of inhibitor 7 at 0, 0.5 or 1 µM. (D) Graphical representation of data
in (C).
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Scheme 1. Synthesis of Compounds 7, 13 – 19a
a Reagents and conditions: (a) 1-Chloro-3-iodopropane, K2CO3, CH3CN, reflux; (b) HNO3,
Ac2O, 0 °C to rt, 75% over 2 steps; (c) pyrrolidine, K2CO3, NaI, cat. tetrabutylammonium
iodide, CH3CN, reflux, 81%; (d) Fe dust, NH4OAc, AcOEt, H2O, reflux, 63%; (e) NaOCN,
AcOH, H2O, rt; (f) NaOH, H2O, MeOH, reflux; (g) N,N-diethylaniline POCl3, reflux, 50%
over 3 steps; (h) 1-isopropyl piperidin-4-amines, DIEA, THF, rt, 94%; (i) 1-cyclopropyl
piperidin-4-amines, DIEA, THF, rt, 89%; (j) various amines, i-PrOH, 160 °C, microwave,
74–82%.
Liu et al. Page 22













Scheme 2. Synthesis of Compound 22a
a Reagents and conditions: (a) 4 N HCl, dioxane, tetrahydro-2H–pyran-4-carbonitrile, 100
°C; (b) N,N-diethylaniline, POCl3, reflux, 48% over 2 steps; (c) 1-isopropylpiperidin-4-
amine, K2CO3, DMF, 60 °C, 78%.
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Scheme 3. Synthesis of Compounds 26a and 26ba
a Reagents and conditions: (a) 4,4-difluoropiperidine, K2CO3, NaI, cat. tetrabutylammonium
iodide, CH3CN, reflux, 81%; (b) Fe dust, NH4OAc, AcOEt-H2O, reflux, 60%; (c) 4 N HCl,
dioxane, cyclohexanecarbonitrile or tetrahydro-2H–pyran-4-carbonitrile, 100 °C; (d) N,N-
diethylaniline, POCl3, reflux, 49–53% over 2 steps; (e) 1-isopropylpiperidin-4-amines,
K2CO3, DMF, 60 °C, 75–77%.
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Table 1
SAR of the 2-Amino Moiety.
Compound R1 G9a IC50 (nM)a
5 < 2.5
7 (UNC0642) < 2.5
13 (UNC1479) < 2.5
14 14 ± 0.6
15 26 ± 1
16 < 2.5
17 < 2.5
22 9.0 ± 0.1
a
IC50 determination experiments were performed in triplicate.













Liu et al. Page 26
Table 2
SAR of the N capping of the Upper Piperidine Moiety.
Compound R1 R2 G9a IC50 (nM)a
7 i-propyl < 2.5
18 c-propyl 3.0 ± 0.1
14 i-propyl 14 ± 0.6
19 c-propyl 4.0 ± 0.2
a
IC50 determination experiments were performed in triplicate.
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Table 3
SAR of the 7-Aminoalkoxy Moiety.
Compound R1 R3 G9a IC50 (nM)a
5 < 2.5
26a > 26,000
22 9.0 ± 0.1
26b > 50,000
a
IC50 determination experiments were performed in triplicate.
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Table 4









5 81 11,000 136
7 110 16,700 152
13 180 23,700 132
16 150 7,000 47
17 100 5,700 57
18 310 14,700 47
19 590 > 50,000 > 85
22 310 > 50,000 > 161
a
IC50 or EC50 values are the average of experimental triplicates with standard deviation (SD) values that are about 3-fold less than the average.
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Table 5






7 0.5 > 90
13 0.7 > 90
15 < 0.5 > 90
22 4.7 16
26 7.4 10













Liu et al. Page 30
Table 6


















Plasma and brain concentrations were measured at 8 time points with 3 animals per time point. Clearance, half-life, and volume distribution
values are not reported because only IP administration was performed.
b
The density of brain homogenate was considered as 1 which is equivalent to plasma density (1); Brain concentrations and exposures are expressed
as ng/g and hr*ng/g, respectively.
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Table 7








MDA-MB-231 110 16,700 152
U2OS 130 6,000 46
PC3 130 8,900 68
PANC-1 40 3,500 88
a
IC50 or EC50 values are the average of experimental triplicates with SD values that are about 3-fold less than the average.
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